{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:00:42Z","timestamp":1771041642409,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"S1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1186\/s12859-018-2011-y","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T19:51:50Z","timestamp":1519069910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients"],"prefix":"10.1186","volume":"19","author":[{"given":"In Seok","family":"Yang","sequence":"first","affiliation":[]},{"given":"Sangwoo","family":"Kim","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,2,19]]},"reference":[{"key":"2011_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828\u201351.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2011_CR2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/JTO.0000000000000266","volume":"9","author":"B Izar","year":"2014","unstructured":"Izar B, Zhou H, Heist RS, Azzoli CG, Muzikansky A, Scribner EE, et al. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014;9(9):1363.","journal-title":"J Thorac Oncol"},{"key":"2011_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3816\/CLC.2006.n.030","volume":"8","author":"S Aviel-Ronen","year":"2006","unstructured":"Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer. 2006;8:30\u20138.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"2011_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5732\/cjc.012.10098","volume":"32","author":"PM Westcott","year":"2013","unstructured":"Westcott PM, To MD. The genetics and biology of KRAS in lung cancer. Chin J Cancer. 2013;32(2):63\u201370.","journal-title":"Chin J Cancer"},{"issue":"6","key":"2011_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1586\/14789450.2015.1100079","volume":"12","author":"R Nussinov","year":"2015","unstructured":"Nussinov R, Tsai CJ, Muratcioglu S, Jang H1, Gursoy A, Keskin O. Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation. Expert Rev Proteomics. 2015;12(6):669\u201382.","journal-title":"Expert Rev Proteomics"},{"issue":"7","key":"2011_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/14737159.2016.1181545","volume":"16","author":"R Salgia","year":"2016","unstructured":"Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016;16(7):737\u201349.","journal-title":"Expert Rev Mol Diagn"},{"key":"2011_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1245\/s10434-012-2754-z","volume":"20","author":"JL Guan","year":"2013","unstructured":"Guan JL, Zhong WZ, An SJ, Yang JJ, Su J, Chen ZH, et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol. 2013;20:1381\u20138.","journal-title":"Ann Surg Oncol"},{"key":"2011_CR8","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387:1415\u201326.","journal-title":"Lancet"},{"issue":"1","key":"2011_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.lungcan.2011.01.029","volume":"74","author":"PL Wagner","year":"2011","unstructured":"Wagner PL, Stiedl AC, Wilbertz T, Petersen K, Scheble V, Menon R, et al. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer. 2011;74(1):118\u201323.","journal-title":"Lung Cancer"},{"issue":"9","key":"2011_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/ijc.27879","volume":"132","author":"J Staaf","year":"2013","unstructured":"Staaf J, Isaksson S, Karlsson A, J\u00f6nsson M, Johansson L, J\u00f6nsson P, et al. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer. 2013;132(9):2020\u201331.","journal-title":"Int J Cancer"},{"issue":"1","key":"2011_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/JTO.0b013e31820594f0","volume":"6","author":"H Sasaki","year":"2011","unstructured":"Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol. 2011;6(1):15\u201320.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2011_CR12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/s41598-017-01966-z","volume":"7","author":"JK Rhee","year":"2017","unstructured":"Rhee JK, Lee S, Park WY, Kim YH, Kim TM. Allelic imbalance of somatic mutations in cancer genomes and transcriptomes. Sci Rep. 2017;7(1):1653.","journal-title":"Sci Rep"},{"key":"2011_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1073\/pnas.1412811112","volume":"112","author":"FD Tsai","year":"2015","unstructured":"Tsai FD, Lopes MS, Zhou M, Court H, Ponce O, Fiordalisi JJ, et al. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc Natl Acad Sci U S A. 2015;112:779\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2011_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/acs.jpcb.5b11110","volume":"120","author":"M Chakrabarti","year":"2016","unstructured":"Chakrabarti M, Jang H, Nussinov R. Comparison of the conformations of KRAS isoforms, K-Ras4A and K-Ras4B, points to similarities and significant differences. J Phys Chem B. 2016;120(4):667\u201379.","journal-title":"J Phys Chem B"},{"key":"2011_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/nrg.2016.10","volume":"17","author":"SA Byron","year":"2016","unstructured":"Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016;17:257\u201371.","journal-title":"Nat Rev Genet"},{"key":"2011_CR16","doi-asserted-by":"crossref","unstructured":"Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 511(28):511\u20135.","DOI":"10.1038\/nbt.1621"},{"key":"2011_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290\u20135.","journal-title":"Nat Biotechnol"},{"key":"2011_CR18","unstructured":"The Cancer Genome Atlas. Available at: https:\/\/cancergenome.nih.gov\/ . Accessed at 1 Feb 2017."},{"key":"2011_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/s12864-016-2852-6","volume":"17","author":"IS Yang","year":"2016","unstructured":"Yang IS, Son H, Kim S, Kim S. ISOexpresso: a web-based platform for isoform-level expression analysis in human cancer. BMC Genomics. 2016;17:631.","journal-title":"BMC Genomics"},{"key":"2011_CR20","unstructured":"Genomic Data Commons Legacy Archive. Available at: https:\/\/portal.gdc.cancer.gov\/legacy-archive\/search\/f . Accessed at 1 Feb 2017."},{"key":"2011_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"key":"2011_CR22","unstructured":"FireBrowse. Available at: http:\/\/firebrowse.org\/ . Accessed at 15 April 2016."},{"key":"2011_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543\u201350.","journal-title":"Nature"},{"key":"2011_CR24","doi-asserted-by":"publisher","first-page":"E3050","DOI":"10.1073\/pnas.1508057112","volume":"112","author":"CL Barrett","year":"2015","unstructured":"Barrett CL, DeBoever C, Jepsen K, Saenz CC, Carson DA, Frazer KA. Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy. Proc Natl Acad Sci U S A. 2015;112:E3050\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2011_CR25","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1093\/nar\/gkv210","volume":"43","author":"M Danan-Gotthold","year":"2015","unstructured":"Danan-Gotthold M, Golan-Gerstl R, Eisenberg E, Meir K, Karni R, Levanon EY. Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Res. 2015;43:5130\u201344.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2011_CR26","doi-asserted-by":"publisher","first-page":"e86837","DOI":"10.1172\/jci.insight.86837","volume":"1","author":"D Djureinovic","year":"2016","unstructured":"Djureinovic D, Hallstr\u00f6m BM, Horie M, Mattsson JS, la Fleur L, Fagerberg L, et al. Profiling cancer testis antigens in non-small-cell lung cancer. JCI Insight. 2016;1(10):e86837.","journal-title":"JCI Insight"},{"issue":"11","key":"2011_CR27","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1101\/gr.145144.112","volume":"22","author":"JS Seo","year":"2012","unstructured":"Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22(11):2109\u201319.","journal-title":"Genome Res"},{"issue":"15","key":"2011_CR28","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1200\/JCO.2011.38.6359","volume":"30","author":"ED Saad","year":"2012","unstructured":"Saad ED, Buyse M. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol. 2012;30(15):1750\u20134.","journal-title":"J Clin Oncol"},{"key":"2011_CR29","unstructured":"International Cancer Genome Consortium. Available at: http:\/\/icgc.org\/ . Accessed at 15 April 2016."},{"key":"2011_CR30","unstructured":"Project Genomics Evidence Neoplasia Information Exchange. Available at: http:\/\/www.aacr.org\/Research\/Research\/Pages\/aacr-project-genie.aspx . Accessed 8 June 2017."}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-018-2011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T05:08:37Z","timestamp":1570770517000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-018-2011-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":30,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["2011"],"URL":"https:\/\/doi.org\/10.1186\/s12859-018-2011-y","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"19 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"40"}}